Loading stock data…
$29.89+0.09 (+0.30%)
Hemab Therapeutics Holdings, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$26.08M↓ | -$23.61M↓ | -$16.06M↑ | -$16.56M |
| Net Income | -$24.15M↓ | -$22.69M↓ | -$12.21M↑ | -$15.31M |
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its pr...